CAS: 115344-47-3 - Siguazodan
Formula:C14H16N6O
InChI:InChI=1S/C14H16N6O/c1-9-7-12(21)19-20-13(9)10-3-5-11(6-4-10)18-14(16-2)17-8-15/h3-6,9H,7H2,1-2H3,(H,19,21)(H2,16,17,18)
InChI key:InChIKey=NUHPODZZKHQQET-UHFFFAOYSA-N
SMILES:N#CNC(=NC=1C=CC(=CC1)C2=NNC(=O)CC2C)NC
- Synonyms:
- 1-Cyano-2-Methyl-3-[4-(4-Methyl-6-Oxo-1,4,5,6-Tetrahydropyridazin-3-Yl)Phenyl]Guanidine
- Guanidine, N-cyano-N′-methyl-N′′-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-
- N-Cyano-N'-Methyl-N'-[4-(1,4,5,6-Tetrahydro-4-Methyl-6-Oxo-3-Pyridazinyl)Phenyl]Guanidine
- N-Cyano-Nmethyl-N��-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]guanidine
- Siguazodan (SKF 94836)
- Siguazodan, N-Cyano-Nμ-methyl-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]guanidine
- Sk And F-94836
- Skf 94836
- Siguazodan
Guanidine, N-cyano-N'-methyl-N''-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-
CAS:115344-47-3
Formula:
C14H16N6O
Purity:
99%
Color and Shape:
Solid
Molecular weight:
284.3164
Ref: IN-DA000GMB
1mg | 156.00 € | ||
5mg | 324.00 € | ||
10mg | 645.00 € | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire | ||
200mg | To inquire |
Estimated delivery in United States, on Wednesday 13 Nov 2024
Siguazodan
CAS:115344-47-3
Siguazodan is a phosphodiesterase inhibitor that is used for the treatment of congestive heart failure …
Formula:
C14H16N6O
Purity:
Min. 95%
Molecular weight:
284.32 g/mol
Ref: 3D-QEA34447
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Friday 27 Dec 2024
Siguazodan
CAS:115344-47-3
Siguazodan (SKF 94836) is an effective, selective, orally active phosphodiesterase III ((PDE-III)) inhibitor with an …
Formula:
C14H16N6O
Purity:
99.63% - 99.77%
Color and Shape:
Solid
Molecular weight:
284.32
Ref: TM-T12913
1mg | 84.00 € | ||
5mg | 164.00 € | ||
10mg | 250.00 € | ||
25mg | 414.00 € | ||
50mg | 583.00 € | ||
100mg | 786.00 € | ||
200mg | 1,054.00 € | ||
1mL*10mM (DMSO) | 236.00 € |
Estimated delivery in United States, on Wednesday 15 Jan 2025